ArticleScientific reports2025
Efficacy and safety of taxane plus ramucirumab for advanced gastric cancer after chemotherapy plus nivolumab.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Chemotherapy After Immune Checkpoint Inhibitor Exposure in Advanced Gastric Cancer: Clinical Evidence and Treatment Sequencing in the ICI Era.Journal of gastrointestinal cancer · 2026Review
- Pathological Complete Response in a Patient With HER2-Negative Esophagogastric Junction Cancer Undergoing Conversion-Intent Surgery After Ramucirumab Plus Paclitaxel Following Nivolumab-Based Chemotherapy: A Case Report.Journal of gastrointestinal cancer · 2026Article
- Real-world sequential treatment patterns and outcomes in the new era of immunotherapy for advanced gastric cancer in Japan.Future oncology (London, England) · 2026Article
- Targeting the remodeled peritoneal ecosystem: a paradigm shift from tumor cells to the microenvironment in gastric cancer peritoneal metastasis.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeTaxane plus ramucirumab (RAM) is the standard second-line treatment for advanced gastric cancer (AGC). However, data on second-line therapy following first-line treatment with nivolumab remains limited. This study aimed to evaluate the efficacy, safety, and prognostic factors of taxane plus RAM in patients with advanced AGC who previously received chemotherapy plus nivolumab. MATERIALS AND
methodsWe collected data from AGC patients at multiple institutions who received taxane plus RAM after failure of chemotherapy plus nivolumab. All patients received first-line chemotherapy with nivolumab before December 2022.
resultsIn total, 51 patients received taxane plus RAM (41 received paclitaxel plus RAM, and ten received nab-paclitaxel plus RAM). The median age was 70 years (range 41-83), 30 (59%) patients were male, and 45 (89%) had PS 0/1. Fourteen patients (27%) had liver metastases, 30 (59%) had peritoneal dissemination, and 25 (49%) had ascites; 43 patients had measurable lesions, nine (21%) achieved a partial response, and 21 (49%) achieved stable disease. Median progression-free survival was 3.7 months (95% confidence interval (CI) 3.1-5.1) and median overall survival was 8.9 months (95% CI 6.3-11.6). Major adverse events of grade 3 or higher were neutropenia (41%), anemia (10%), febrile neutropenia (8%), proteinuria (6%), and infection (4%). Multivariate analysis showed that ascites was a poor prognostic factor for overall survival.
conclusionTaxane plus RAM was effective in patients with AGC who have received prior chemotherapy plus nivolumab. The presence of ascites may be a poor prognostic factor in patients receiving taxane plus RAM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.